title: Investigating cardiovascular risk reduction--the Rosuvastatin GALAXY Programme.
abstract: The GALAXY Programme is a comprehensive global research initiative that will address several important unanswered questions in statin research and investigate the impact of rosuvastatin on cardiovascular risk reduction and patient outcomes. Studies already completed demonstrate that rosuvastatin provides greater reductions in low-density lipoprotein cholesterol (LDL-C) than other statins, enabling more patients to achieve LDL-C treatment goals. Additionally, rosuvastatin provides beneficial effects on other components of the atherogenic lipid profile. Ongoing studies will evaluate whether these effects translate into beneficial effects on atherosclerosis and significant reductions in cardiovascular events. Important information will also be provided on the role of statins in less well studied groups, including patients with heart failure, end stage renal disease, and individuals without elevated LDL-C but at heightened vascular risk as a result of increased systemic inflammation. Ultimately, the GALAXY Programme will provide clinical data that will enable physicians to make more effective statin treatment decisions, which will lead to improved patient care and cardiovascular outcomes.
authors.affiliation: Humboldt University, Berlin, Germany. schuster@infogen.de
authors.forename: Herbert
authors.initials: H
authors.lastname: Schuster
authors.forename: Jonathan C
authors.initials: JC
authors.lastname: Fox
mesh_terms: D002318:Cardiovascular Diseases / Q000145:classification / Q000453:epidemiology / Q000517:prevention & control*; D003625:Data Collection; D004311:Double-Blind Method; D005464:Fluorobenzenes / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D008077:Lipoproteins, LDL / Q000037:antagonists & inhibitors / Q000096:biosynthesis / Q000187:drug effects; D015201:Meta-Analysis as Topic; D011743:Pyrimidines / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D040242:Risk Reduction Behavior; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D005464:Fluorobenzenes; D008077:Lipoproteins, LDL; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium